Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

David Camidge

Concepts (579)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
186
2025
1046
35.980
Why?
Lung Neoplasms
234
2025
2329
34.650
Why?
Protein Kinase Inhibitors
99
2025
872
14.120
Why?
Receptor Protein-Tyrosine Kinases
48
2025
221
11.060
Why?
Antineoplastic Agents
78
2024
2060
9.690
Why?
Pyrimidines
39
2025
445
8.310
Why?
Pyrazoles
48
2024
405
7.360
Why?
Antineoplastic Combined Chemotherapy Protocols
48
2025
1573
7.230
Why?
ErbB Receptors
61
2025
603
6.690
Why?
Pyridines
38
2021
477
6.520
Why?
Proto-Oncogene Proteins c-met
25
2025
74
6.430
Why?
Organophosphorus Compounds
18
2025
78
6.380
Why?
Gene Rearrangement
26
2022
146
5.340
Why?
Immunoconjugates
10
2025
102
4.600
Why?
Protein-Tyrosine Kinases
29
2024
430
4.600
Why?
Brain Neoplasms
31
2024
1164
4.310
Why?
Drug Resistance, Neoplasm
35
2025
750
3.900
Why?
Mutation
64
2025
3700
3.790
Why?
Oncogenes
10
2025
109
3.470
Why?
Proto-Oncogene Proteins
29
2024
634
3.380
Why?
Acrylamides
16
2025
58
3.290
Why?
Antibodies, Monoclonal, Humanized
22
2025
764
2.980
Why?
Carbazoles
14
2024
84
2.850
Why?
Neoplasms
31
2025
2475
2.830
Why?
Biomarkers, Tumor
27
2025
1185
2.760
Why?
Humans
302
2025
129128
2.740
Why?
Thoracic Neoplasms
4
2025
35
2.690
Why?
Clinical Trials as Topic
18
2025
1000
2.590
Why?
Small Cell Lung Carcinoma
15
2024
89
2.570
Why?
Middle Aged
145
2025
31080
2.570
Why?
Piperidines
13
2024
190
2.550
Why?
Aniline Compounds
14
2025
98
2.490
Why?
Aged
124
2025
22090
2.440
Why?
Adenocarcinoma
16
2017
889
2.250
Why?
Proto-Oncogene Proteins p21(ras)
15
2025
259
2.240
Why?
Aged, 80 and over
67
2025
7066
2.150
Why?
Molecular Targeted Therapy
16
2025
387
2.120
Why?
Male
155
2025
63202
1.900
Why?
Antibodies, Monoclonal
20
2025
1359
1.890
Why?
Female
157
2025
68518
1.830
Why?
Radiosurgery
13
2024
318
1.800
Why?
Quinazolines
12
2024
243
1.720
Why?
Adult
112
2025
35513
1.720
Why?
Receptor, ErbB-2
10
2024
336
1.720
Why?
Lactams, Macrocyclic
10
2024
49
1.670
Why?
Oncogene Proteins, Fusion
8
2021
198
1.660
Why?
Medical Oncology
5
2025
274
1.570
Why?
In Situ Hybridization, Fluorescence
15
2021
313
1.570
Why?
High-Throughput Nucleotide Sequencing
5
2025
485
1.540
Why?
Erlotinib Hydrochloride
13
2022
68
1.540
Why?
Gene Amplification
10
2025
103
1.520
Why?
Neoplasm Staging
31
2025
1293
1.490
Why?
Pemetrexed
8
2024
32
1.440
Why?
Lung Diseases, Interstitial
5
2022
597
1.440
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
5
2013
29
1.440
Why?
Survival Rate
26
2024
1875
1.420
Why?
Neoplasm Recurrence, Local
6
2025
963
1.370
Why?
Mesothelioma
4
2018
38
1.370
Why?
Prognosis
32
2025
3788
1.370
Why?
Clinical Trials, Phase I as Topic
4
2024
50
1.320
Why?
Central Nervous System
4
2021
255
1.310
Why?
Circulating Tumor DNA
5
2025
29
1.260
Why?
Retrospective Studies
44
2025
14571
1.260
Why?
Disease-Free Survival
26
2020
656
1.240
Why?
Gene Dosage
4
2018
142
1.210
Why?
Lactams
10
2024
21
1.200
Why?
Treatment Outcome
47
2025
10227
1.180
Why?
Maximum Tolerated Dose
21
2025
194
1.170
Why?
Cell-Free Nucleic Acids
4
2022
31
1.150
Why?
Cell Adhesion Molecules
3
2025
172
1.140
Why?
Trastuzumab
3
2022
100
1.080
Why?
Imidazoles
4
2018
229
1.070
Why?
Disease Progression
19
2025
2613
1.060
Why?
Exons
12
2025
338
1.050
Why?
Camptothecin
5
2022
107
1.050
Why?
Piperazines
3
2019
337
1.040
Why?
Neoplasm Metastasis
13
2024
616
1.020
Why?
Indoles
12
2025
372
1.010
Why?
Immunotherapy
6
2025
588
1.010
Why?
Cell Cycle
6
2012
581
0.970
Why?
Aminopyridines
10
2024
96
0.970
Why?
B7-H1 Antigen
6
2024
189
0.950
Why?
Response Evaluation Criteria in Solid Tumors
6
2022
17
0.940
Why?
Follow-Up Studies
26
2024
4915
0.940
Why?
Apoptosis
8
2023
2438
0.920
Why?
Proto-Oncogene Proteins c-ret
2
2021
29
0.890
Why?
Pleural Neoplasms
3
2018
23
0.860
Why?
DNA Copy Number Variations
7
2024
169
0.860
Why?
Research Personnel
1
2025
160
0.840
Why?
Survival Analysis
12
2025
1265
0.820
Why?
Glomerular Filtration Rate
3
2019
682
0.810
Why?
Neuregulin-1
2
2021
46
0.810
Why?
Pyridazines
3
2019
50
0.790
Why?
Paclitaxel
9
2020
215
0.790
Why?
Hypogonadism
2
2013
83
0.780
Why?
Endpoint Determination
5
2018
75
0.770
Why?
Glutamates
6
2014
56
0.770
Why?
Guanine
6
2014
76
0.760
Why?
Carboplatin
11
2021
140
0.750
Why?
Dose-Response Relationship, Drug
13
2021
1945
0.730
Why?
ras Proteins
8
2014
145
0.720
Why?
Central Nervous System Neoplasms
5
2023
148
0.710
Why?
Patient Selection
5
2019
665
0.710
Why?
Authorship
1
2021
45
0.710
Why?
Receptor, Fibroblast Growth Factor, Type 1
2
2018
52
0.700
Why?
Carcinoma, Renal Cell
2
2013
180
0.690
Why?
Antineoplastic Agents, Immunological
2
2019
174
0.670
Why?
Biomarkers
8
2019
3896
0.660
Why?
Genomics
1
2025
716
0.660
Why?
Kidney
2
2019
1308
0.650
Why?
Pneumonia
2
2022
599
0.640
Why?
Taxoids
6
2023
95
0.630
Why?
Antigens, Neoplasm
4
2025
310
0.620
Why?
Testosterone
2
2013
379
0.620
Why?
Drug-Related Side Effects and Adverse Reactions
3
2020
256
0.620
Why?
Proto-Oncogene Proteins B-raf
4
2018
215
0.610
Why?
Kidney Neoplasms
2
2013
350
0.600
Why?
Thromboembolism
1
2018
102
0.580
Why?
Cyclin-Dependent Kinases
2
2010
130
0.570
Why?
Kaplan-Meier Estimate
14
2020
864
0.570
Why?
Drug Administration Schedule
10
2017
758
0.570
Why?
Young Adult
22
2020
12389
0.550
Why?
Pyrazines
2
2019
88
0.550
Why?
Healthcare Disparities
2
2021
581
0.540
Why?
Creatinine
2
2019
475
0.540
Why?
Triazoles
3
2025
152
0.520
Why?
Receptors, Fibroblast Growth Factor
2
2016
65
0.510
Why?
Liver Neoplasms
2
2019
643
0.500
Why?
Mouth Mucosa
2
2006
89
0.500
Why?
Hair
2
2006
74
0.490
Why?
Etoposide
5
2024
150
0.490
Why?
Cranial Irradiation
7
2022
68
0.480
Why?
Cohort Studies
14
2024
5407
0.470
Why?
Nitrofurantoin
1
2014
7
0.460
Why?
Anti-Infective Agents, Urinary
1
2014
13
0.450
Why?
Cystitis
1
2014
22
0.450
Why?
Kelch-Like ECH-Associated Protein 1
2
2024
10
0.440
Why?
RNA, Messenger
3
2018
2676
0.440
Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
20
0.440
Why?
Crown Ethers
1
2013
4
0.440
Why?
Signal Transduction
8
2014
4838
0.430
Why?
Blood-Brain Barrier
2
2016
129
0.410
Why?
Carcinoma, Squamous Cell
5
2019
621
0.410
Why?
Insulin-Like Growth Factor II
2
2009
25
0.400
Why?
Point Mutation
1
2013
224
0.390
Why?
Receptors, Platelet-Derived Growth Factor
1
2012
14
0.390
Why?
Smoking
2
2018
1466
0.390
Why?
Organoplatinum Compounds
3
2012
40
0.390
Why?
Tissue Distribution
5
2020
291
0.390
Why?
Clinical Trials, Phase II as Topic
2
2024
71
0.390
Why?
Receptor, IGF Type 1
1
2012
66
0.380
Why?
Sulfonamides
5
2020
500
0.380
Why?
Androgens
1
2013
174
0.370
Why?
Translocation, Genetic
1
2012
98
0.370
Why?
Carcinoma, Large Cell
1
2011
15
0.370
Why?
Cell Proliferation
8
2014
2347
0.360
Why?
Cisplatin
5
2024
298
0.360
Why?
Apoptosis Regulatory Proteins
1
2011
182
0.360
Why?
Adolescent
14
2022
20302
0.350
Why?
Keratin-18
1
2010
10
0.350
Why?
Drug Therapy, Combination
1
2013
1013
0.340
Why?
Adenocarcinoma, Bronchiolo-Alveolar
2
2016
19
0.340
Why?
Estrenes
1
2010
16
0.340
Why?
Lymphatic Metastasis
2
2009
318
0.340
Why?
Benzamides
2
2022
195
0.340
Why?
Mutagenesis, Insertional
3
2025
65
0.340
Why?
Insulin-Like Growth Factor I
2
2009
307
0.330
Why?
Antimitotic Agents
1
2009
8
0.330
Why?
Receptors, Somatomedin
1
2009
4
0.330
Why?
Research Design
6
2024
1040
0.330
Why?
Chemoradiotherapy
3
2022
209
0.320
Why?
Lung
4
2019
3752
0.320
Why?
Caspase 3
1
2010
229
0.320
Why?
Estradiol
2
2010
497
0.320
Why?
Cell Line, Tumor
11
2024
3184
0.320
Why?
Genetic Testing
3
2015
427
0.320
Why?
Antineoplastic Agents, Phytogenic
2
2001
186
0.320
Why?
Catheter Ablation
1
2012
332
0.320
Why?
Genotype
5
2021
1832
0.300
Why?
Programmed Cell Death 1 Receptor
3
2019
227
0.300
Why?
Mitosis
1
2009
178
0.300
Why?
Sulfones
4
2021
109
0.300
Why?
Oligonucleotides, Antisense
1
2008
106
0.290
Why?
Lymph Node Excision
1
2009
165
0.290
Why?
Quality of Life
6
2025
2694
0.280
Why?
Immunohistochemistry
5
2022
1671
0.280
Why?
Administration, Oral
8
2015
759
0.280
Why?
HIV
1
2008
226
0.280
Why?
Cyclin-Dependent Kinase Inhibitor Proteins
1
2006
7
0.270
Why?
Registries
5
2024
1884
0.270
Why?
Accidents
1
2007
40
0.270
Why?
Quinazolinones
3
2016
19
0.260
Why?
Ethics, Medical
1
2006
78
0.260
Why?
Pharmacology
1
2005
8
0.250
Why?
Pharmacokinetics
1
2005
23
0.250
Why?
Time Factors
7
2021
6518
0.250
Why?
Technology, Pharmaceutical
1
2005
18
0.250
Why?
Tumor Microenvironment
3
2024
622
0.250
Why?
Canada
2
2025
348
0.240
Why?
Animals
19
2024
34600
0.240
Why?
DNA, Neoplasm
2
2019
159
0.240
Why?
Karyopherins
1
2025
17
0.240
Why?
Precision Medicine
4
2019
384
0.230
Why?
Cough
2
2017
116
0.230
Why?
Mortality
1
2007
308
0.230
Why?
Prospective Studies
7
2023
7079
0.230
Why?
CTLA-4 Antigen
1
2024
89
0.230
Why?
Immunoenzyme Techniques
3
2014
206
0.220
Why?
Phenylurea Compounds
2
2016
89
0.220
Why?
Leukocytes, Mononuclear
1
2006
538
0.220
Why?
Cost-Benefit Analysis
3
2021
582
0.220
Why?
Radiotherapy Dosage
3
2017
249
0.210
Why?
RNA
3
2019
883
0.210
Why?
Combined Modality Therapy
5
2017
1209
0.210
Why?
Clinical Trials, Phase III as Topic
2
2024
90
0.210
Why?
United States
7
2025
13940
0.200
Why?
Platinum
1
2023
44
0.200
Why?
Pyrroles
3
2012
192
0.200
Why?
Tumor Burden
3
2018
283
0.200
Why?
Fertility
1
2024
162
0.200
Why?
NF-E2-Related Factor 2
1
2023
67
0.200
Why?
Oligopeptides
1
2024
258
0.200
Why?
DNA Mutational Analysis
3
2019
386
0.190
Why?
Treatment Failure
3
2014
343
0.190
Why?
Carcinoma, Transitional Cell
1
2022
60
0.190
Why?
Tomography, X-Ray Computed
5
2022
2541
0.190
Why?
Benzodiazepinones
1
2021
16
0.190
Why?
Indazoles
1
2022
66
0.190
Why?
Nails, Malformed
1
2001
5
0.190
Why?
Lymphoma, Follicular
1
2021
38
0.180
Why?
Fatigue
5
2015
320
0.180
Why?
Carcinoma, Small Cell
1
2001
168
0.180
Why?
Skin
1
2005
719
0.180
Why?
Breast Neoplasms
3
2020
2150
0.180
Why?
Carcinogenesis
1
2022
209
0.180
Why?
Biopsy
3
2013
1086
0.180
Why?
Recurrence
3
2018
1003
0.180
Why?
Epidermal Cyst
1
2000
12
0.170
Why?
Pregnancy
2
2024
6375
0.170
Why?
Neovascularization, Pathologic
3
2012
291
0.170
Why?
Bevacizumab
2
2019
131
0.170
Why?
Retreatment
2
2017
70
0.170
Why?
Meningeal Neoplasms
1
2021
93
0.170
Why?
Standard of Care
1
2020
71
0.170
Why?
Quality-Adjusted Life Years
2
2021
108
0.170
Why?
Radiodermatitis
1
2000
8
0.170
Why?
Proto-Oncogene Proteins c-bcl-2
2
2012
235
0.170
Why?
Suicide
1
2007
587
0.170
Why?
Deglutition Disorders
1
2001
131
0.170
Why?
Oncogene Protein p21(ras)
1
2019
16
0.170
Why?
Policy
1
2021
145
0.170
Why?
Positron-Emission Tomography
4
2014
283
0.170
Why?
Consolidation Chemotherapy
1
2019
9
0.160
Why?
Diarrhea
2
2017
177
0.160
Why?
Urinary Bladder Neoplasms
1
2022
226
0.160
Why?
Organs at Risk
1
2019
31
0.160
Why?
Lymphoma, B-Cell
1
2000
104
0.160
Why?
Diagnostic Imaging
1
2022
330
0.160
Why?
Aminoquinolines
1
2019
21
0.160
Why?
Oncogene Proteins
1
2019
52
0.160
Why?
Carcinoma, Lewis Lung
1
2019
13
0.160
Why?
Vascular Endothelial Growth Factor A
3
2012
501
0.160
Why?
Radiotherapy, Conformal
2
2017
70
0.160
Why?
Lymphoma, Large B-Cell, Diffuse
1
2000
113
0.160
Why?
Incidence
3
2020
2635
0.160
Why?
Gene Fusion
1
2018
24
0.160
Why?
Antinematodal Agents
1
2018
6
0.150
Why?
CD8-Positive T-Lymphocytes
1
2025
847
0.150
Why?
Motivation
1
2023
546
0.150
Why?
Radiotherapy
3
2016
185
0.150
Why?
Gold
1
2019
118
0.150
Why?
Multivariate Analysis
2
2019
1496
0.150
Why?
Drug Approval
1
2018
86
0.150
Why?
Cytotoxicity, Immunologic
1
2018
218
0.140
Why?
MAP Kinase Signaling System
1
2019
303
0.140
Why?
Chemotherapy, Adjuvant
3
2022
376
0.140
Why?
Proportional Hazards Models
3
2020
1210
0.140
Why?
Diagnosis, Differential
2
2014
1417
0.140
Why?
Immunity, Cellular
1
2019
267
0.140
Why?
Drowning
1
2017
7
0.140
Why?
Hospitalization
1
2007
2077
0.140
Why?
Thymus Neoplasms
1
2017
22
0.140
Why?
Thymoma
1
2017
31
0.140
Why?
Receptors, Growth Factor
3
2011
46
0.140
Why?
Scotland
2
2007
12
0.140
Why?
Benzimidazoles
3
2018
158
0.140
Why?
Nausea
1
2017
108
0.130
Why?
Head and Neck Neoplasms
1
2021
534
0.130
Why?
Pleural Effusion, Malignant
1
2016
10
0.130
Why?
Adjuvants, Immunologic
1
2017
221
0.130
Why?
Real-Time Polymerase Chain Reaction
2
2014
326
0.130
Why?
Headache
1
2017
138
0.130
Why?
Centrosome
1
2016
64
0.130
Why?
Xenograft Model Antitumor Assays
4
2024
813
0.130
Why?
Decision Trees
1
2016
89
0.130
Why?
Markov Chains
1
2016
116
0.130
Why?
Proto-Oncogene Proteins c-kit
1
2016
68
0.130
Why?
Chronic Disease
2
2014
1707
0.120
Why?
Risk Assessment
5
2015
3260
0.120
Why?
Peritoneal Neoplasms
1
2016
87
0.120
Why?
Postoperative Care
1
2017
243
0.120
Why?
Randomized Controlled Trials as Topic
2
2018
1363
0.120
Why?
Radiotherapy, Adjuvant
2
2022
211
0.120
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2014
940
0.120
Why?
Drug Interactions
2
2013
360
0.120
Why?
Neutropenia
4
2019
136
0.120
Why?
Structure-Activity Relationship
2
2018
531
0.110
Why?
Cryptogenic Organizing Pneumonia
1
2014
17
0.110
Why?
Magnetic Resonance Imaging
5
2018
3383
0.110
Why?
Brain
3
2024
2628
0.110
Why?
Australia
2
2012
246
0.110
Why?
Thoracic Surgery, Video-Assisted
1
2014
43
0.110
Why?
HIV Infections
1
2008
2715
0.110
Why?
Reproducibility of Results
3
2006
3033
0.110
Why?
Genetic Predisposition to Disease
2
2018
2267
0.110
Why?
Vascular Endothelial Growth Factor Receptor-2
2
2013
81
0.110
Why?
Sequence Analysis, DNA
2
2014
773
0.110
Why?
Periodicals as Topic
1
2016
206
0.110
Why?
Threonine
1
2013
44
0.110
Why?
Disease Management
2
2020
593
0.100
Why?
Sex Hormone-Binding Globulin
1
2013
54
0.100
Why?
HSP90 Heat-Shock Proteins
1
2013
45
0.100
Why?
Skin Neoplasms
1
2000
833
0.100
Why?
Sodium-Phosphate Cotransporter Proteins, Type IIb
1
2012
9
0.100
Why?
GTP Phosphohydrolases
1
2013
84
0.100
Why?
Methionine
1
2013
157
0.100
Why?
Focal Adhesion Kinase 2
1
2012
4
0.100
Why?
Luteinizing Hormone
1
2013
178
0.100
Why?
Serum Albumin
1
2013
145
0.100
Why?
Biomedical Research
2
2010
647
0.100
Why?
Electronic Health Records
2
2024
976
0.100
Why?
Dyspnea
1
2014
239
0.100
Why?
Heterozygote
1
2013
267
0.100
Why?
Focal Adhesion Kinase 1
1
2012
29
0.100
Why?
Thiophenes
1
2013
119
0.100
Why?
Biological Transport
1
2013
394
0.100
Why?
Quinolines
1
2013
154
0.090
Why?
Genes, ras
1
2012
98
0.090
Why?
Platelet-Derived Growth Factor
1
2012
89
0.090
Why?
Hydroxamic Acids
1
2012
88
0.090
Why?
Blotting, Western
2
2014
1169
0.090
Why?
Follicle Stimulating Hormone
1
2013
239
0.090
Why?
Immunosuppressive Agents
1
2016
690
0.090
Why?
Niacinamide
1
2012
73
0.090
Why?
Biomarkers, Pharmacological
1
2011
26
0.090
Why?
Radiation Pneumonitis
1
2011
28
0.090
Why?
Hyperglycemia
1
2015
326
0.090
Why?
Area Under Curve
2
2012
282
0.090
Why?
Models, Molecular
2
2018
1483
0.090
Why?
Induction Chemotherapy
1
2011
70
0.090
Why?
Phytotherapy
1
2011
76
0.090
Why?
Vimentin
1
2011
50
0.090
Why?
Genes, bcl-2
1
2011
20
0.090
Why?
Rats
2
2010
5173
0.090
Why?
Glioma
1
2015
354
0.090
Why?
Fluorouracil
2
2012
197
0.090
Why?
Heterogeneous-Nuclear Ribonucleoprotein L
1
2010
2
0.090
Why?
Heptanoic Acids
1
2011
62
0.090
Why?
Caspase 9
1
2010
54
0.090
Why?
Deoxycytidine
2
2011
164
0.090
Why?
X-Linked Inhibitor of Apoptosis Protein
1
2010
12
0.090
Why?
Amino Acid Chloromethyl Ketones
1
2010
24
0.090
Why?
Alcohol Drinking
1
2017
751
0.090
Why?
Cysteine Proteinase Inhibitors
1
2010
48
0.090
Why?
In Situ Nick-End Labeling
1
2010
120
0.090
Why?
Multicenter Studies as Topic
1
2011
287
0.090
Why?
Histone Deacetylase Inhibitors
1
2012
206
0.090
Why?
Transplantation, Heterologous
1
2010
187
0.090
Why?
Neoplasm Transplantation
1
2010
258
0.080
Why?
Caspase Inhibitors
1
2010
77
0.080
Why?
Cadherins
1
2011
186
0.080
Why?
Immunoblotting
1
2010
300
0.080
Why?
Cannabinoids
1
2011
132
0.080
Why?
Mice
7
2024
16644
0.080
Why?
Cognition
2
2016
1111
0.080
Why?
Insulin-Like Growth Factor Binding Proteins
1
2009
29
0.080
Why?
RNA Precursors
1
2010
147
0.080
Why?
Protein Structure, Tertiary
1
2012
836
0.080
Why?
Epithelial-Mesenchymal Transition
1
2011
199
0.080
Why?
Pharmacogenetics
1
2010
171
0.080
Why?
Demography
1
2010
277
0.080
Why?
Weight Loss
1
2014
724
0.080
Why?
Dogs
1
2010
366
0.080
Why?
Alternative Splicing
1
2010
218
0.080
Why?
RNA Interference
1
2010
441
0.080
Why?
Species Specificity
1
2010
570
0.080
Why?
Floxuridine
1
2008
5
0.070
Why?
Radiotherapy Planning, Computer-Assisted
1
2009
123
0.070
Why?
Protein Kinase C beta
1
2008
21
0.070
Why?
Angiogenesis Inhibitors
1
2010
216
0.070
Why?
Marijuana Smoking
1
2011
239
0.070
Why?
Medical Records
1
2009
170
0.070
Why?
Polymerase Chain Reaction
1
2011
1021
0.070
Why?
Practice Guidelines as Topic
1
2016
1493
0.070
Why?
Enzyme-Linked Immunosorbent Assay
1
2010
816
0.070
Why?
Capecitabine
1
2008
47
0.070
Why?
Risk Factors
4
2019
9769
0.070
Why?
Double-Blind Method
2
2016
1865
0.070
Why?
Clinical Decision-Making
2
2022
305
0.070
Why?
Salvage Therapy
2
2019
138
0.070
Why?
Sensitivity and Specificity
2
2018
1825
0.070
Why?
TNF-Related Apoptosis-Inducing Ligand
1
2007
43
0.070
Why?
Everolimus
2
2020
68
0.070
Why?
Antibiotics, Antineoplastic
1
2008
120
0.070
Why?
Health Services Accessibility
1
2014
897
0.070
Why?
Retinoblastoma Protein
1
2006
54
0.070
Why?
Scalp
1
2006
35
0.070
Why?
Membrane Proteins
1
2013
1109
0.070
Why?
Protein Kinase C
1
2008
253
0.070
Why?
Placebos
1
2006
201
0.070
Why?
Receptors, Vascular Endothelial Growth Factor
1
2006
89
0.070
Why?
Tumor Suppressor Protein p53
1
2010
508
0.060
Why?
Cell Line
1
2012
2737
0.060
Why?
Neoplasm Proteins
1
2009
421
0.060
Why?
Receptors, Estrogen
1
2008
429
0.060
Why?
Cetuximab
2
2017
94
0.060
Why?
Hair Follicle
1
2005
45
0.060
Why?
Colorectal Neoplasms
1
2013
753
0.060
Why?
Melanocytes
1
2005
69
0.060
Why?
Tumor Cells, Cultured
2
2019
930
0.060
Why?
Reference Values
1
2006
780
0.060
Why?
Hydrazines
1
2025
34
0.060
Why?
Oncolytic Virotherapy
1
2024
13
0.060
Why?
Monocytes
1
2008
543
0.060
Why?
Cannabis
1
2011
436
0.060
Why?
Safety
1
2006
329
0.060
Why?
Models, Biological
1
2012
1695
0.060
Why?
Cross-Over Studies
1
2006
513
0.060
Why?
Genes, Tumor Suppressor
1
2024
86
0.060
Why?
Carcinoma, Neuroendocrine
1
2024
32
0.060
Why?
Class I Phosphatidylinositol 3-Kinases
2
2014
81
0.060
Why?
Risk
1
2007
856
0.060
Why?
Nitric Oxide Synthase Type II
1
2024
167
0.060
Why?
Specimen Handling
1
2005
165
0.060
Why?
Adenoviridae
1
2024
190
0.050
Why?
Phosphorylation
1
2008
1687
0.050
Why?
Genetic Vectors
1
2024
311
0.050
Why?
Delivery of Health Care
1
2010
894
0.050
Why?
5'-Nucleotidase
1
2023
37
0.050
Why?
Phosphatidylinositol 3-Kinases
2
2014
357
0.050
Why?
MAP Kinase Kinase 1
2
2014
76
0.050
Why?
Tumor Suppressor Proteins
1
2024
313
0.050
Why?
Pharyngeal Diseases
1
2001
14
0.050
Why?
Gene Expression Regulation, Neoplastic
2
2019
1353
0.050
Why?
Heparin, Low-Molecular-Weight
1
2021
29
0.050
Why?
Antibodies, Bispecific
1
2022
49
0.050
Why?
Esophageal Diseases
1
2001
27
0.050
Why?
Opportunistic Infections
1
2001
47
0.050
Why?
Mediastinal Neoplasms
1
2001
38
0.050
Why?
Asia
1
2021
58
0.050
Why?
Sex Characteristics
1
2006
727
0.050
Why?
Ligands
1
2023
614
0.050
Why?
Mice, SCID
2
2013
347
0.050
Why?
United States Food and Drug Administration
1
2022
198
0.050
Why?
Drug Combinations
1
2022
329
0.040
Why?
Gastrointestinal Neoplasms
1
2001
72
0.040
Why?
Brain Stem Neoplasms
1
2001
89
0.040
Why?
Carbon Monoxide
1
2020
68
0.040
Why?
Surveys and Questionnaires
1
2013
5377
0.040
Why?
Europe
1
2021
362
0.040
Why?
Neoplasms, Second Primary
1
2001
108
0.040
Why?
Thrombocytopenia
2
2012
182
0.040
Why?
Focal Adhesion Protein-Tyrosine Kinases
1
2019
34
0.040
Why?
Ipilimumab
1
2019
31
0.040
Why?
Comparative Effectiveness Research
1
2020
151
0.040
Why?
Age Factors
1
2007
3120
0.040
Why?
Consensus
1
2022
638
0.040
Why?
Tuberculosis, Pulmonary
1
2000
137
0.040
Why?
Lymphopenia
1
2019
59
0.040
Why?
Drug Monitoring
1
2020
184
0.040
Why?
Leukocyte Count
1
2019
328
0.040
Why?
Liquid Biopsy
1
2018
8
0.040
Why?
Genes, erbB-1
1
2018
17
0.040
Why?
Radiotherapy, Intensity-Modulated
1
2019
128
0.040
Why?
Radiation Dosage
1
2019
153
0.040
Why?
Genome, Human
1
2000
392
0.040
Why?
Organoids
1
2019
105
0.040
Why?
Immune System
1
2019
177
0.040
Why?
Practice Patterns, Physicians'
1
2006
1270
0.040
Why?
Topoisomerase I Inhibitors
1
2017
17
0.040
Why?
DNA Topoisomerases, Type I
1
2017
16
0.040
Why?
Intention to Treat Analysis
1
2017
70
0.030
Why?
Lymphocytes
1
2019
369
0.030
Why?
Feasibility Studies
1
2020
862
0.030
Why?
Exosomes
1
2018
96
0.030
Why?
Exanthema
1
2017
73
0.030
Why?
Hyperphosphatemia
1
2016
15
0.030
Why?
Lymphocytes, Tumor-Infiltrating
1
2019
209
0.030
Why?
Mice, Inbred BALB C
1
2019
1230
0.030
Why?
Palliative Care
2
2014
721
0.030
Why?
T-Lymphocytes
1
2024
1924
0.030
Why?
Genetic Heterogeneity
1
2016
57
0.030
Why?
Myalgia
1
2015
13
0.030
Why?
Drug Therapy
1
2016
76
0.030
Why?
Creatine Kinase
1
2015
75
0.030
Why?
Karnofsky Performance Status
1
2015
38
0.030
Why?
Aspartate Aminotransferases
1
2015
85
0.030
Why?
Heart
1
2019
639
0.030
Why?
Alanine Transaminase
1
2015
150
0.030
Why?
Edema
1
2015
125
0.030
Why?
Constipation
1
2015
89
0.030
Why?
Gonanes
1
2014
27
0.030
Why?
Proto-Oncogenes
1
2014
29
0.030
Why?
Texas
1
2014
227
0.030
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2014
136
0.030
Why?
Multiplex Polymerase Chain Reaction
1
2014
51
0.030
Why?
United Kingdom
1
2014
259
0.030
Why?
Computational Biology
1
2018
598
0.030
Why?
Neutrophils
1
2019
1195
0.030
Why?
Amino Acid Substitution
1
2014
281
0.030
Why?
Vision Disorders
1
2014
136
0.030
Why?
Epidermal Growth Factor
1
2013
169
0.030
Why?
Inhibitory Concentration 50
1
2013
81
0.030
Why?
PTEN Phosphohydrolase
1
2014
157
0.030
Why?
Recombination, Genetic
1
2014
189
0.030
Why?
Syndecan-4
1
2012
7
0.030
Why?
Guidelines as Topic
1
2014
261
0.030
Why?
Antigens, Differentiation, B-Lymphocyte
1
2012
37
0.030
Why?
Sirolimus
1
2013
189
0.030
Why?
Proto-Oncogene Proteins c-akt
1
2014
421
0.020
Why?
Pyrimidinones
1
2013
102
0.020
Why?
Leucovorin
1
2012
68
0.020
Why?
Metabolic Clearance Rate
1
2012
103
0.020
Why?
Cytochrome P-450 CYP3A Inhibitors
1
2012
20
0.020
Why?
Midazolam
1
2012
48
0.020
Why?
Gene Frequency
1
2013
504
0.020
Why?
Biological Availability
1
2011
123
0.020
Why?
Cytochrome P-450 CYP3A
1
2012
66
0.020
Why?
Nonlinear Dynamics
1
2012
88
0.020
Why?
Radiopharmaceuticals
1
2012
166
0.020
Why?
Pyridones
1
2013
160
0.020
Why?
Databases, Factual
1
2017
1279
0.020
Why?
Fluorodeoxyglucose F18
1
2012
127
0.020
Why?
Mice, Nude
1
2013
683
0.020
Why?
Receptor, ErbB-4
1
2011
18
0.020
Why?
Genetic Association Studies
1
2013
361
0.020
Why?
Mutation, Missense
1
2013
318
0.020
Why?
Silencer Elements, Transcriptional
1
2010
1
0.020
Why?
Histocompatibility Antigens Class II
1
2012
360
0.020
Why?
Cell Survival
1
2013
1077
0.020
Why?
MAP Kinase Kinase 2
1
2010
28
0.020
Why?
Meta-Analysis as Topic
1
2011
169
0.020
Why?
Capsules
1
2010
37
0.020
Why?
Molecular Diagnostic Techniques
1
2011
97
0.020
Why?
Serine Endopeptidases
1
2010
117
0.020
Why?
Socioeconomic Factors
1
2014
1210
0.020
Why?
Isoenzymes
1
2010
304
0.020
Why?
Alopecia
1
2009
28
0.020
Why?
Vascular Endothelial Growth Factor Receptor-1
1
2010
66
0.020
Why?
Microtubule-Associated Proteins
1
2010
190
0.020
Why?
Infusions, Intravenous
1
2010
385
0.020
Why?
Precancerous Conditions
1
2010
161
0.020
Why?
Enzyme Inhibitors
1
2012
811
0.020
Why?
Mice, Inbred C57BL
1
2019
5284
0.020
Why?
RNA, Small Interfering
1
2010
571
0.020
Why?
Anemia
1
2009
161
0.020
Why?
Substrate Specificity
1
2008
367
0.020
Why?
Evidence-Based Medicine
1
2012
718
0.020
Why?
Hormone Replacement Therapy
1
2008
91
0.020
Why?
Cell Cycle Proteins
1
2010
580
0.020
Why?
California
1
2008
400
0.020
Why?
DNA Repair
1
2008
205
0.020
Why?
Neoplastic Stem Cells
1
2010
386
0.020
Why?
Early Detection of Cancer
1
2010
372
0.020
Why?
DNA Damage
1
2008
364
0.020
Why?
Pain
1
2011
760
0.020
Why?
Colorado
1
2014
4396
0.010
Why?
MicroRNAs
1
2010
677
0.010
Why?
Genome-Wide Association Study
1
2010
1337
0.010
Why?
Predictive Value of Tests
1
2008
1943
0.010
Why?
Gambia
1
2000
14
0.010
Why?
X Chromosome
1
2000
51
0.010
Why?
Chromosomes, Human, Pair 15
1
2000
56
0.010
Why?
Nuclear Family
1
2000
51
0.010
Why?
South Africa
1
2000
192
0.010
Why?
Genetic Linkage
1
2000
299
0.010
Why?
Microsatellite Repeats
1
2000
162
0.010
Why?
Genetic Markers
1
2000
339
0.010
Why?
Chromosome Mapping
1
2000
505
0.010
Why?
Camidge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)